Document:

Exhibit 10.4

 

 

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT
AGREEMENT (the “Agreement”) is made and entered into as of January 1, 2017, by and between Rancho Santa Fe
Mining, Inc., a Nevada corporation with its principal place of business located at  500 Rainbow Blvd, Suite
300, Las Vegas, NV 89107 (the “Company”), and Jeffrey Hallman, an individual and resident of the State of
California (“Employee” and together with the Company, the “Parties” and each, a
“Party”).

 

RECITALS

A.
The Company wishes to employ Employee because Employee possesses certain knowledge and skills relating to the Company’s
business, structure and operations that the Company wishes to retain for the development and success of the Company’s business.

B.
The Company wishes to employ Employee, and Employee wishes to be employed by the Company, on the terms and conditions contained
herein.

NOW, THEREFORE,
in consideration of the premises set forth above and for other good and valuable consideration mutually exchanged by the Parties,
the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1.  
Employment; Duties. The Company hereby employs Employee, and Employee hereby accepts employment, subject to the terms
and conditions set forth in this Agreement. As an employee of the Company, Employee shall have such duties, responsibilities and
authority as are commensurate and consistent with such position and as may, from time to time, be assigned to him by the executive
officers (the “Officers”) and/or the board of directors (the “Board”) of the Company. During
the Term (as defined herein), Employee shall devote his full business time and efforts to the performance of his duties hereunder,
unless otherwise explicitly authorized by the Board. Notwithstanding the foregoing, the expenditure of reasonable amounts of time
by Employee for the making of passive personal investments, the conduct of private business affairs, and charitable activities
shall be allowed, provided that such activities do not materially interfere with the services required to be rendered to
the Company hereunder and do not violate the restrictive covenants set forth herein.

2.  
Term of Employment. The term of Employee’s employment hereunder, unless sooner terminated as provided herein
(the “Initial Term”), shall be for a period of one (1) year, having commenced on January 1, 2017 (the “Commencement
Date”).

3.  
Compensation of Employee.

(a)
Base Salary. Beginning on the Effective Date, the Company agrees to pay the Employee a base salary at the monthly
rate of Five Thousand Dollars ($5,000). All salary or other compensation payable to the Employee shall be subject to the customary
withholding, FICA, medical and other tax and other employment taxes and deductions as required by federal, state and local law
with respect to compensation paid by an employer to an employee.

(b)
Expenses. Pursuant to the Company’s customary policies in force at the time of payment, Employee shall be promptly
reimbursed, against presentation of vouchers or receipts therefor, for all expenses properly and reasonably incurred by Employee
on behalf of the Company in the performance of Employee’s duties hereunder.

(c)
Benefits. Employee shall be entitled to participate in such pension, profit sharing, group insurance, hospitalization,
and group health (for Employee and his immediate family) and benefit plans and all other benefits and plans, including perquisites,
if any, as the Company provides to its employees (the “Benefit Plans”).

4.  
Termination; Disability; Resignation; Termination Without Cause. 

(a)
Termination for Cause. The Company shall have the right to terminate the Employee’s employment hereunder for
Cause. Upon such termination for Cause, Employee shall have no further duties or obligations under this Agreement (except as provided
in Section 5) and the obligations of the Company to Employee shall be as set forth below. For purposes of this Agreement, “Cause”
shall mean:

(i)Employee’s
indictment or conviction of a felony or any crime involving moral turpitude under federal, state or local law;

(ii)Employee’s
failure to perform (other than as a result of Employee’s being Disabled), in any material respect, any of his duties or obligations
under or in accordance with this Agreement for any reason whatsoever, including, without limitation, failure to execute or comply
with a direction of the Officers or Board, and the Employee fails to cure such failure within ten (10) business days following
receipt of notice from the Company, or, if such failure cannot be cured within such ten (10) business day period, Employee fails
to initiate a cure within such ten (10) business day period;

(iii)Employee
commits any dishonest, malicious or grossly negligent act which is materially detrimental to the business or reputation of the
Company, or the Company’s business relationships, provided, however, that in such event the Company shall give the Employee
written notice specifying in reasonable detail the reason for the termination;

(iv)Any intentional
misapplication by Employee of the Company’s funds or other material assets, or any other act of dishonesty injurious to the
Company committed by Employee; or

(v)Employee’s
use or possession of any controlled substance or chronic abuse of alcoholic beverages, which use or possession the Officers or
Board reasonably determines renders Employee unfit to serve in his capacity as an employee of the Company.

In the event
the Company terminates the Employee’s employment for Cause, then the Employee shall be entitled to receive only such compensation,
expenses and/or benefits that have been earned, accrued or vested as of the date of such termination (collectively, “Accrued
Obligations”).

(b)
Disability. The Company shall have the right to terminate the Employee’s employment hereunder by reason of
the Employee’s becoming Disabled for an aggregate period of ninety (90) days in any consecutive three hundred sixty (360)
day period (the “Disability Period”).

(i)“Disabled”
as used in this Agreement means that, by reason of physical or mental incapacity, Employee shall fail or be unable to substantially
perform the essential duties of his employment with or without reasonable accommodation.

(ii)In the
event Employee is Disabled, during the period of such disability he shall continue to receive his base compensation in the amount
set forth in Section 3(a) hereof, which base compensation shall be reduced by the amount of all disability benefits he actually
receives under any disability insurance program in place with the Company until the first to occur of (1) the cessation of the
Disability or (2) the termination of this Agreement by the Company. During the period of Disability and prior to termination, the
Employee shall continue to receive the benefits provided in Section 3 hereof.

(iii)If the
Employee is terminated at the end of the Disability Period, then the Employee shall receive only such compensation, expenses and/or
benefits that have been earned, accrued or vested as of the date of such termination.

(c)
Death. The Company’s employment of the Employee shall terminate upon his death and all payments and benefits
shall cease upon such date provided, however, that under this Agreement the estate of such Employee shall be entitled to receive
such compensation, expenses and/or benefits that have been earned, accrued or vested as of the date of such termination.

(d)
Termination by the Employee for Good Reason.

The Employee
may elect, by written notice to the Company, such notice to be effective immediately upon receipt by the Company, to terminate
his employment hereunder if:

(i)The Company
sells all or substantially all of its assets and the Employee is not retained or otherwise has his employment terminated;

(ii)The Company
merges or consolidates with another business entity in a transaction immediately following which the holders of all of the outstanding
shares of the voting capital stock of the Company own less than a majority of the outstanding shares of the voting capital stock
of the resulting entity (whether or not the resulting entity is the Company); provided, however, that the Employee shall not be
permitted to terminate his employment under this subsection unless he notifies the Company in writing that he does not approve
of the directors selected to serve on the Board after the merger or similar transaction described herein; or

(iii)The Company
defaults in making any of the payments required under this Agreement and said default continues for a ninety (90) day period after
the Employee has given the Company written notice of the payment default.

If the Employee
elects to terminate his employment hereunder pursuant to this Section 4(d), then the Company shall continue to pay to the Employee
his base salary and all benefits owed hereunder through the end of the current Term.

(e)
Resignation. If the Employee voluntarily resigns during the Term of this Agreement or any Renewal Term other than
pursuant to Section 4(d) hereof, then all payments and benefits shall cease on the effective date of resignation, provided that
under this Agreement the Employee shall be entitled to receive such compensation, expenses and/or benefits that have been earned,
accrued or vested as of and through the date of such termination, such date of termination to be mutually agreed upon between the
Employee and the Company.

(f)
Termination Without Cause. The Company may terminate this Agreement at any time, for any reason, or for no reason,
effective immediately upon notice to Employee, delivered in accordance with Section 6 of this Agreement, stating Company’s
intention to terminate this Agreement. If the Company terminates this Agreement pursuant to this Section 4(f) during the Term of
this Agreement or any renewal term, then the Company shall continue to pay to the Employee his base salary hereunder through the
end of the current Term and shall receive all Accrued Obligations as of the date of such termination.

5.  
Covenants.

(a)
Confidentiality.

(i)
Proprietary Information. Employee understands and acknowledges
that, during the course of his employment with the Company, Employee shall create and has created, as well as shall be granted
and has been granted access to, certain valuable information relating to the business of the Company that provides the Company
with a competitive advantage (or that which could be used to the disadvantage of the Company by a Competitive Business, as defined
herein), which is not generally known by, nor easily learned or determined by, persons outside the Company (collectively referred
to herein as “Proprietary Information”) including, but not limited to: Developments (as defined herein), the
Company’s products, applications, methods, trade secrets and other intellectual property, the research, development, procedures,
manuals, confidential reports, technical information, financial information, business plans, prospects of opportunities, purchasing,
operating and other cost data, employee information (including, but not limited to, personnel, payroll, compensation and benefit
data and plans), including all such information recorded in manuals, memoranda, projections, reports, minutes, plans, drawings,
sketches, designs, formula books, data, specifications, software programs and records, whether or not legended or otherwise identified
by the Company as Proprietary Information, as well as such information that is the subject of meetings and discussions and not
recorded. Proprietary Information shall not include such information that Employee can demonstrate is generally available to the
public (other than as a result of a disclosure by Employee).

(ii)
Duty of Confidentiality. Employee agrees at all times, both during
and after Employee’s employment with the Company, (i) to hold all Proprietary Information in a confidential manner for the
benefit of the Company, to reasonably safeguard all such Proprietary Information; and (ii) to adhere to any non-disclosure, confidentiality
or other similar agreements to which Employee or the Company is or becomes a party or subject thereto. Employee also agrees that
he shall not, directly or indirectly, disclose any such Proprietary Information to, or use such Proprietary Information for the
benefit of, any third person or entity outside the Company, except to persons identified in writing by the Company. Employee further
agrees that, in addition to enforcing this restriction, the Company may have other rights and remedies under the common law or
applicable statutory laws relating to the protection of trade secrets. 

(iii)
Investors, Other Third-Parties, and Goodwill. Employee acknowledges
that all Company Investors, together with all distributors, representatives, agents, licensees and third-parties (“Other
Third Parties”) that the Employee interacts and works with while employed by Company, are doing business with the Company
and not with the Employee, personally, and that in the course of dealing with such Investors and Other Third Parties, the Company
has established goodwill with respect to each such Investor and Other Third Party that is created and maintained at the Company’s
expense (“Third-Party Goodwill”). Employee also acknowledges that, by virtue of his employment with the Company,
he has gained or will gain knowledge of the business needs of, and other information concerning, the Investors and Other Third
Parties, and that Employee will inevitably have to draw on such information if Employee solicits or provides services to any Investor
or Other Third Parties on his own behalf or on behalf of a Competitive Business. For purposes of this Agreement, “Competitive
Business” shall mean any enterprise engaged in any business that is substantially similar to that which the Company is
engaged, or plans to be engaged, so long as Employee is directly involved in such business or planned business on behalf of the
Company. 

(iv)  
Nondisparagement. The Employee agrees that at no time during his
employment by the Company or thereafter, shall he make, or cause or assist any other person to make, any statement or other communication
to any third party which impugns or attacks, or is otherwise critical of, the reputation, business or character of the Company
or any of its respective directors, officers or employees.

(b)
Restrictions on Solicitation. Employee shall not, directly or indirectly, without the prior written consent and approval
of the Company, (i) interfere with or attempt to interfere with the relationship between any person who is, or was during
the then most recent three (3) month period, an employee, agent, representative or independent contractor of the Company, or solicit,
induce or attempt to solicit or induce any of them to leave the employ or service of the Company or to violate the terms of their
respective contracts, agreements or any employment arrangements with the Company; or (ii) induce or attempt to induce any customer,
client, supplier, distributor, licensee or other business relation of the Company to cease doing business with the Company, or
in any way interfere with the contract or relationship between the Company and any customer, client, supplier, distributor, licensee
or other business relation of the Company. As used herein, the term “indirectly” shall include, without limitation,
Employee’s permitting the use of Employee’s name by any Competitive Business to induce or interfere with any employee
or business relationship of the Company.

(c)
Restrictions on Employee’s Competitive Employment. In order to protect the Company’s Proprietary Information
and Third-Party Goodwill, Employee acknowledges and agrees that in the event this Agreement is terminated for any reason, then,
from the date of such termination, or from the last date upon which severance is paid to Employee, whichever is later, and for
a period of one (1) year thereafter, the Employee shall not, without the Company’s express written consent, directly
or indirectly, own, control, manage, operate, participate in, be employed by, permit the use of his name with, or act for or on
behalf of, any Competitive Business which competes directly with the Company and its products. The Employee agrees that the restriction
on competitive employment contemplated herein is necessary and reasonable in order to protect the Company in the conduct of its
business.

(d)
Assignment of Developments.

(i)
Employee acknowledges and agrees that all developments, including, without
limitation, the creation of new products, devices, inventions, discoveries, concepts, ideas, improvements, patents, trademarks,
trade names, trade dress, service marks, copyrights, domain names, trade secrets, designs, works, reports, computer software or
systems, flow charts, diagrams, procedures, data, documentation, and writings and applications thereof, including all results and
proceeds of the foregoing, relating to the Business or future business of the Company that Employee, alone or jointly with others,
has discovered, suggested, conceived, created, made, developed, reduced to practice, or acquired during Employee’s employment
with or as a result of Employee’s employment with the Company (collectively, “Developments”) are being
prepared by Employee as an employee of the Company within the scope of Employee’s employment and shall be considered as “works
made for hire” and shall remain the sole and exclusive property of the Company, free of any reserved or other rights of any
kind on Employee’s part. If and to the extent the fact that the Developments are works made for hire is not effective to
place ownership of the Developments and all rights therein to the Company, then Employee hereby solely, exclusively and irrevocably
assigns and transfers to the Company any and all of his right, title and interest in and to the Developments. Employee agrees to
disclose to the Company promptly and fully all future Developments and, at any time upon request and at the expense of the Company,
to execute, acknowledge and deliver to the Company all instruments that the Company shall prepare and to take any and all other
actions that are necessary or desirable, in the reasonable opinion of the Company, to evidence or effectuate all or any of the
Company’s rights hereunder, including executing and delivering patent, trademark or copyright applications and instruments
of assignment to the Company and enabling the Company to file instruments of assignment for, to file and prosecute applications
for, and to acquire, maintain, and enforce, all patents, trademarks or copyrights covering the Developments in all countries in
which the same are deemed necessary by the Company. All data, memoranda, notes, lists, drawings, records, files, investor and client/customer
lists, supplier lists, and other documentation (and all copies thereof) made or compiled by Employee or made available to Employee
concerning the Developments or otherwise concerning the past, present, or planned business of the Company are the property of the
Company, and shall be delivered to the Company immediately upon the termination of Employee’s employment with the Company.

(ii)
If any patent, trademark or copyright application is filed by Employee
or on Employee’s behalf during Employee’s employment with the Company or within one (1) year after Employee’s
leaving the Company’s employ, describing a Development within the scope of Employee’s work for the Company or which
otherwise relates to a portion of the business of the Company, of which the Employee had knowledge during Employee’s employment
with the Company, it is to be conclusively presumed that the Development was conceived by Employee during the period of such employment.

(e)
Remedies. Employee acknowledges that the Company has a compelling business interest in preventing unfair competition
stemming from the intentional or inadvertent use or disclosure of the Company’s Proprietary Information. Employee further
acknowledges and agrees that damages for a breach or threatened breach of any of the covenants set forth in this Section 5 will
be difficult to determine and will not afford a full and adequate remedy, and therefore agrees that the Company, in addition to
seeking actual damages in connection therewith and the termination of the Company’s obligations in hereunder, may seek specific
enforcement of any such covenant in any court of competent jurisdiction, including, without limitation, by the issuance of a temporary
or permanent injunction without the necessity of showing any actual damages or posting any bond or furnishing any other security,
and that the specific enforcement of the provisions of this Agreement will not diminish Employee’s ability to earn a livelihood
or create or impose upon Employee any undue hardship. Employee also agrees that any request for such relief by the Company shall
be in addition to, and without prejudice to, any claim for monetary damages that the Company may elect to assert.

(f)
Rights to Materials and Return of Materials. All papers, files, notes, correspondence, lists, software, software
code, memoranda, e-mails, price lists, plans, sketches, documents, reports, records, data, research, proposals, specifications,
technical information, models, flow charts, schematics, tapes, printouts, designs, graphics, drawings, photographs, abstracts,
summaries, charts, graphs, notebooks, investor lists, customer/client lists, information on the use, development and integration
of software, information relating to the research, development, preparation, maintenance and sale of any Company created products,
including RF or Microwave products, and all other compilations of information, regardless of how such information may be recorded
and whether in printed form or on a computer or magnetic disk or in any other medium (together with all copies of such documents
and things) relating to the Business of the Company or containing Proprietary Information and/or Developments, which Employee shall
use or prepare or come in contact with in the course of, or as a result of, Employee’s employment by the Company shall, as
between the parties to this Agreement, remain the sole property of the Company. Laptop computers, other computers, software and
related data, information and other property provided to Employee by the Company or obtained by Employee, directly or indirectly,
from the Company, also shall remain the sole property of the Company. Upon the termination of Employee’s employment or upon
the prior demand of the Company, Employee shall immediately return all such materials and things to the Company and shall not retain
any copies or remove or participate in removing any such materials or things from the premises of the Company after termination
or the Company’s request for return.

6.  
Notices. Any notice or communication given by either Party hereto to the other shall be in writing and personally delivered
or mailed by registered or certified mail, return receipt requested, postage prepaid, to the following addresses:

	If to the Company:	Rancho Santa Fe Mining, Inc.
	 	500 Rainbow Blvd
	 	Suite 300
	 	Las Vegas, CA 89107
	 	Attention: Michael Midlam, CEO
	 	Facsimile: [858-717-8090]
	 	 
	With a copy, that shall not	 
	constitute notice, to:	Lucosky Brookman LLP
	 	101 Wood Avenue South, 5th Floor
	 	Woodbridge, New Jersey 08830
	 	Facsimile: (732) 396-4401
	 	 
	If to Employee:	Jeffrey Hallman
	 	16727 Open View Rd.
	 	Ramona, CA 92065

 

Any notice shall be deemed
given when actually delivered to such address, or two (2) days after such notice has been mailed or sent by Federal Express, whichever
comes earliest. Any person entitled to receive notice may designate in writing, by notice to the other, such other address to which
notices to such person shall thereafter be sent.

 

7.  
Miscellaneous.

(a)
Representations and Covenants. In order to induce the Company to enter into this Agreement, the Employee makes the
following representations and covenants to the Company and acknowledges that Company is relying upon such representations and covenants:

(i)
No agreements or obligations exist to which the Employee is a party or
otherwise bound, in writing or otherwise, that in any way interfere with, impede or preclude him from fulfilling any and all of
the terms and conditions of this Agreement. 

(ii)
Employee, during his employment, shall use his best efforts to disclose
to the Board, in writing, or by other effective method, any bona fide information known by him, which he reasonably believes is
not known to the Board, and which he reasonably believes would have any material negative impact on the Company.

(b)
Entire Agreement. This Agreement contains the entire understanding of the Parties with respect to the subject matter
contained herein and supersedes the effectiveness all other prior agreements and understandings between the Parties or between
Employee and the Company with respect to such subject matter.

(c)
Amendment; Waiver. The Parties agree that this Agreement may not be amended, supplemented, canceled or discharged,
except by written instrument executed by the Party against whom enforcement is sought. No failure to exercise, and no delay in
exercising, any right, power or privilege hereunder shall operate as a waiver thereof. No waiver of any breach of any provision
of this Agreement shall be deemed to be a waiver of any preceding or succeeding breach of the same or any other provision.

(d)
Binding Effect; Assignment. The rights and obligations of this Agreement shall bind and inure to the benefit of any
successor of the Company by reorganization, merger or consolidation, or any assignee of all or substantially all of the Company’s
business. Employee’s rights or obligations under this Agreement may not be assigned by Employee.

(e)
Headings. The headings contained in this Agreement are for reference purposes only and shall not affect the meaning
or interpretation of this Agreement.

(f)
Governing Law; Jurisdiction; Interpretation. This Agreement shall be construed in accordance with and governed for
all purposes, by the laws and public policy of the State of Nevada, except as it pertains to conflict of laws principles. Jurisdiction
and venue shall be conferred upon the state and federal courts located in the State of Nevada.

(g)
Further Assurances. Each of the Parties agree to execute, acknowledge, deliver and perform, and cause to be executed,
acknowledged, delivered and performed, at any time, and from time to time, as the case may be, all such further acts, deeds, assignments,
transfers, conveyances, powers of attorney and assurances as may be reasonably necessary to carry out the provisions or intent
of this Agreement.

(h)
Severability. The Parties have carefully reviewed the provisions of this Agreement and agree that they are fair and
equitable. However, in light of the possibility of differing interpretations of law and changes in circumstances, the Parties further
agree that if any one or more of the provisions of this Agreement shall be determined by a court of competent jurisdiction to be
invalid, void or unenforceable, the remainder of the provisions of this Agreement shall, to the extent permitted by law, remain
in full force and effect and shall in no way be affected, impaired or invalidated. Moreover, if any of the provisions contained
in this Agreement are determined by a court of competent jurisdiction to be excessively broad as to duration, activity or subject,
it shall be construed, by limiting or reducing it to the extent legally permitted, so as to be enforceable to the maximum extent
compatible with then applicable law.

(i)
Withholding Taxes. All payments hereunder shall be subject to any and all applicable federal, state, local and foreign
withholding taxes.

(j)
Compliance with Section 409A. Notwithstanding anything herein to the contrary, (i) if at the time of Employee’s
termination of employment with the Company the Employee is a “specified employee” as defined in Section 409A of the
Internal Revenue Code of 1986, as amended (the “Code”), and the deferral of the commencement of any payments
or benefits otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated
or additional tax under Section 409A of the Code, then the Company shall defer the commencement of the payment of any such payments
or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Employee) until the date
that is six (6) months following Employee’s termination of employment with the Company (or the earliest date as is permitted
under Section 409A of the Code) and (ii) if any other payments of money or other benefits due to Employee hereunder could cause
the application of an accelerated or additional tax under Section 409A of the Code, such payments or other benefits shall be deferred
if deferral will make such payment or other benefits compliant under Section 409A of the Code, or otherwise such payment or other
benefits shall be restructured, to the extent possible, in a manner, determined by the Board, that does not cause such an accelerated
or additional tax while, to the extent possible, preserving the overall economic benefit to the Employee of such payments or benefits.
The Company shall consult with Employee in good faith regarding the implementation of the provisions of this Section 7.10; provided
that neither the Company nor any of its officers, directors, shareholders, employees, agents or representatives shall have any
liability to the Employee with respect thereto.

(k)
Survival. Notwithstanding the termination of the Employee’s employment hereunder, the terms, conditions and
provisions contained herein shall survive such termination.

(l)
Counterparts. The Parties agree that this Agreement may be signed in two (2) or more counterparts, each of which
shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same instrument.

 

 

[Signature Page
Follows]

    	 

    	 

    

 

IN WITNESS WHEREOF,
the Parties hereto have executed, or have caused to have executed, this Agreement as of the day and year first above written.Exhibit 10.17

 

BIONDVAX PHARMACEUTICALS LTD.

AND

ANGLES INVESTMENTS IN HI TECH
LTD.

INVESTMENT AGREEMENT

DATED DECEMBER
31, 2016 

THIS INVESTMENT AGREEMENT
(THE "SUBSCRIPTION AGREEMENT") RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT
U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "1933
ACT"). 

NONE OF THE SECURITIES TO
WHICH THIS SUBSCRIPTION AGREEMENT RELATES HAVE BEEN REGISTERED UNDER THE 1933 ACT OR ANY U.S. STATE SECURITIES LAWS AND, UNLESS
SO REGISTERED, NONE MAY BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED HEREIN)
EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF
THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING
THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE 1933 ACT.

 

    
	Biondvax Investment Agreement	 	Page 1  of Page 13

     

    

 

Investment
AGREEMENT

 

This
investment Agreement (the “Agreement”) is made and entered into as of December 31, 2016 (the “Effective
Date”), by and between BiondVax Pharmaceuticals Ltd., of 14 Einstein
Street, Nes-Ziona 74140, Israel (the “Company”), and Angels Investments in Hi Tech Ltd., having its business offices
at ____________ (“Investor”). The Company and the Investor each are referred herein as a "Party"
and together as the "Parties".

 

	Whereas,	the Company is a public company incorporated in Israel, whose shares are traded respectively on
The Tel-Aviv Stock Exchange Ltd. ("TASE") and the NASDAQ Capital Market;
	 	 
	And Whereas	the Investor desires
                                         to invest in the Company and in exchange, the Company is interested in issuing Company’s
                                         securities to the Investor pursuant to the terms and conditions more fully set forth
                                         in this Agreement.

 

Now,
Therefore, the Parties hereby agree as follows:

		1.	The investment

		1.1	Subject to the terms and conditions of this Agreement, subject to the receipt of the Board of Directors'
approval and TASE approval for listing of the Company's shares, the Investor shall invest in the Company the amount of NIS 10,904,749
(ten million nine hundred and four thousand seven hundred and forty nine New Israeli Shekels) (the “Investment”)
within Three (3) business days following the fulfillment of all the conditions set forth in Section 4 below (the "Closing").
The Investment amount may be paid, as per the Investor's decision, in Shekels or US dollars according to the last reported exchange
rate by the Bank of Israel (SHA'AR YATZIG) at the Date of Investment payment.

		1.2	In exchange for the Investment subject to the terms and conditions hereof and pursuant to the transfer
of the Investment to the Company's Bank Account (as defined below), and at Closing, the Company shall issue to the Investor 33,760,832
(thirty three million seven hundred and sixty thousand eight hundred and thirty-two) TASE registerable newly issued ordinary shares
0.0000001 par value each of the Company (the "Shares"). Each Share issued under this Agreement is priced at NIS
0.323 that is the closing price of the Company's shares on the TASE on December 29, 2016.

		1.3	Without giving effect to the transactions contemplated by this Agreement, as of the date hereof,
the Shares represent 24.99% of the issued and outstanding capital of the Company prior to the issuance of the Shares.

		1.4	The transaction contemplated by this Agreement shall not be deemed effective until such time as
all the conditions to closing set forth in this Agreement are fully met, all the Shares are duly issued to the Investors and the
entire Investment is paid to the Company.

    
	Biondvax Investment Agreement	 	Page 2  of Page 13

     

    

 

		1.5	The Investor shall transfer the Investment to the Company’s bank account, the details of
which are as follows (the "Company's Bank Account"):
	 	 	Account Name: BiondVax Pharmaceuticals Ltd.

                              Account Number: 500104/57

                              Swift: LUMIILITXXX 

                              IBAN: IL200108640000050010457

		1.6	The Shares issuance, and delivery of Shares to the Investor pursuant to Section 1.2 shall be evidenced
by electronic share certificates issued to a registration company or one or more certificates dated the Closing Date and bearing
appropriate legends, and by a duly signed Company Shareholder Register.

		1.7	The Shares issued pursuant to Section 1.2, when issued, sold and delivered in accordance with the
terms of this Agreement, including payment of the Investment shall be newly, duly and validly issued, fully paid and non-assessable.

		1.8	The Shares shall be restricted for trade according to Section 5 set forth below.

		1.9	At part of the Investment, subject to meeting all requirements by law and providing requisite documents
necessary for a public Company for such appointment ,a person elected by the Investor shall be appointed as a director to the Company's
board of directors (the "Board") at the Closing as part of the Board Approval (as defined below), effective immediately
and automatically upon the termination of service of Dr. Liora Katzenstein as a director in the Company which shall take effect
on January 10, 2017. In addition to the appointment of a director upon termination of the service of Dr. Liora Katzenstein, the
Company undertakes to make best efforts to cause to the convene the 2017 annual meeting of the Company by not later than May 31,
2017, and in such meeting, make best efforts to support the appointment of the above mentioned director and one additional director
elected by the Investor instead of the directors that their service will be terminated in such meeting (including by proposing
amendments to the terms of the articles of association of the Company if necessary).

		2.	Representations and Warranties of the investor 

The
Investor represents, warrants, covenants and agrees that:

		2.1	The Investor has full power and authority and has taken all required action necessary to permit
it to execute and deliver and to carry out the terms of this Agreement and that this Agreement is valid and binding upon it.

		2.2	The consummation of the transaction contemplated hereunder and the performance by such Investor
do not violate the provisions of any applicable law or instrument to which the Investor is a party.

 

    
	Biondvax Investment Agreement	 	Page 3  of Page 13

     

    
 

		2.3	The Investor acknowledges that it had the opportunity to ask questions of, and receive publicly
available information from, management of the Company concerning the terms and conditions of this transaction and the activity
of the Company and its obligations and liabilities, subject to the Company’s confidentiality obligations pursuant to the
Israeli Securities Law and Securities Regulations and pursuant to the U.S. securities rules.

		2.4	Other than the Company's public reports, and the terms, representations and warranties contained
in this Agreement, no additional material information, representation, assurance and/or forecast with respect to the Company's
business activity were given to the Investor by the Company and/or the Company's representatives. In deciding to enter into this
Agreement, the Investor did not rely on any information or documentation not disclosed in this Agreement or that are not publicly
disclosed.

		2.5	Reserved.

		2.6	The Investor acknowledges that the offer and sale of the Shares have not been registered under
the Securities Act, or the securities laws of any state or regulatory body in US and are being offered and sold in reliance upon
exemptions from the registration requirements of the Securities Act and such laws and may not be transferred or resold without
registration under such laws unless an exemption is available. The Shares will be imprinted with a legend in substantially the
following form:

“THE OFFER AND SALE OF THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES
LAWS OF ANY STATE AND SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED, OR OTHERWISE DISPOSED OF EXCEPT
PURSUANT TO A REGISTRATION STATEMENT WITH RESPECT TO SUCH SECURITIES WHICH IS EFFECTIVE UNDER SUCH ACT AND UNDER ANY APPLICABLE
STATE SECURITIES LAWS UNLESS, IN THE OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY, AN EXEMPTION FROM THE REGISTRATION
REQUIREMENTS OF SUCH ACT AND STATE SECURITIES LAWS IS AVAILABLE.”

		2.7	The Investor is acquiring the Shares for investment
and not with a view to the resale or distribution thereof and is acquiring such securities for its own account.

		2.8	The Investor is an "accredited investor" (as that term is defined in Rule 501 of Regulation
D promulgated under the Securities Act), is sophisticated in financial matters and is familiar with the business of the Company
so that it is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own
interests.

		2.9	The Investors acknowledges that as a result of the receipt of Shares in consideration to the Investment
he may be deemed an "affiliate" of the Company as defined under the U.S. Securities Act and U.S. Securities rules promulgated
hereunder, and undertakes to comply with any applicable law in connection to his status as an "affiliate".

    
	Biondvax Investment Agreement	 	Page 4  of Page 13

     

    

 

		2.10	To the Investor's knowledge, he is not currently the subject of any sanctions administered or enforced
by the U.S. Department of Treasury’s Office of Foreign Assets Control (“OFAC”), the United Nations Security
Council (“UNSC”), the European Union (“EU”), Her Majesty’s Treasury (“HMT”),
or other relevant sanctions authority (collectively, “Sanctions”), nor located, organized or resident in a country
or territory that is the subject of Sanctions.

		2.11	No representations or warranties have been made
to the Investor by the Company or any director, officer, employee, agent or affiliate of the Company, other than the representations
and warranties of the Company set forth herein, and the decision of the Investor to purchase the Shares is based on the representations,
warranties and information contained herein, the Commission Filings and the Investor’s own independent investigation of the
Company.

		3.	Representations and Warranties of the company

The Company represents, warrants, covenants and agrees that:

		3.1	The Company is a publicly traded Israeli Company and the Company's shares are listed for trade
on the TASE and NASDAQ Capital Market, respectively.

		3.2	The consummation of the transaction contemplated hereunder and the performance of this Agreement
by the Company do not violate the provisions of the articles or by-laws of the Company or any applicable law, and will not result
in any breach of, or constitute a default under, any agreement or instrument to which the Company is a party or under which it's
bound.

		3.3	Subject to the receipt of the Board of Directors approval prior to Closing, the Company has full
power and authority and has taken, or will take prior to the Closing Date, all required actions necessary to permit it to execute
and deliver and to carry out the terms of this Agreement and this Agreement is valid and binding upon the Company. The Company
shall take all reasonable actions required to obtain all the Conditions set forth in Section 4 below as soon as possible following
the execution of this Agreement.

		3.4	Except as explicitly provided herein in the legends mentioned in Section, 1.8 and in Section 5,
the Shares shall be issued to the Investor fully paid up in cash, free and clear of any security interests, liens, proxies, voting
trusts and other voting arrangements, calls, third party rights or other commitments of any kind.

		3.5	Immediately following their issuance, the Shares shall represent 19.99% of the issued and outstanding
share capital of the Company and 12.08% of the fully diluted share capital of the Company (including all outstanding options, warrants,
and other securities convertible into shares of the Company, assuming full exercise of all such instruments) ("Fully Diluted").
The Company's Fully Diluted cap table prior and after the execution of this Agreement is attached as Exhibit A.

    
	Biondvax Investment Agreement	 	Page 5  of Page 13

     

    

 

		3.6	Neither this Agreement nor any certificate or other document made or delivered in connection herewith,
contains a knowingly untrue statement of a material fact or knowingly omits to state a material fact necessary to make the statements
herein or therein not missing.

		3.7	To the Company's best knowledge, the execution and delivery by the Company of this Agreement and
the performance by the Company of the transactions contemplated hereby, do not and will not require the Company to effectuate or
obtain any registration with, consent or approval of, or notice to any federal, state or other US governmental authority or regulatory
body, other than periodic and other filings under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
The parties hereto agree and acknowledge that, in making the representations and warranties in the foregoing sentence of this Section,
the Company is relying (among other things) on certain representations and warranties made by the Investors in Section 2.

		3.8	The offering, issuance, sale and delivery of the Shares are exempt from the registration and prospectus
delivery requirements of the Securities Act of 1933, as amended (the “Securities Act”), are being made in compliance
with all applicable federal and (except for any violation or non-compliance that could not reasonably be expected to have a material
adverse effect on the business of the Company) state laws and regulations in the US concerning the offer, issuance and sale of
securities, and are not being issued in violation of any preemptive or other rights of any shareholder of the Company. In making
the representations and warranties in the foregoing sentence of this Section, the Company is relying on the representations and
warranties made by the Investors in Section 2. Neither the Company nor any person acting on its or their behalf, has, directly
or indirectly, made any offers or sales of any security or solicited any offers to buy any security under circumstances that would
cause the offer and/or sale of the Shares under this Agreement to be integrated with prior offerings by the Company for purposes
of the Securities Act.

		3.9	To the Company's best knowledge, he Company has filed all required
forms, reports and other documents with the Israeli and US law, including TASE and NASDAQ, each of which has complied in all material
respects with all applicable requirements of the Israeli and US Securities law and the regulations promulgated thereunder, including
without limitation filing requirements stipulated by the Israeli and US Securities law and the regulations promulgated thereunder
(the "Filing"). Since January 1, 2016, the Company did not
delay any immediate filing with respect to the Israeli and US Securities law and the regulations promulgated thereunder. As of
their respective dates, the Filings did not contain any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements made, in light of the circumstances under which they were made, not misleading. The audited financial
statements and unaudited interim financial statements of the Company included or incorporated by reference in such Filings have
been prepared in accordance with applicable accounting requirements and the published rules and regulations of Israeli and US law,
respectively, with respect thereto, and fairly present, in all material respects, the financial position of the Company as of the
dates thereof and the results of operations for the periods then ended. To the Company’s best knowledge, it was not subject
to any investigation or any similar procedure of TASE or NASDAQ with respect to any failure related to the Filings.

    
	Biondvax Investment Agreement	 	Page 6  of Page 13

     

    
		4.	ConditionS Precedent

		4.1	The closing of the transactions contemplated in Section 1 above will take place at a closing (the
" Closing") which will be held remotely via the exchange of documents and signatures, by no later than January
19, 2017 (provided that the Investor shall have the right to extend such date should the failure to obtain any of the conditions
set forth below is a result of the failure of the Company to perform any of its obligations under this Agreement) or at such other
time as agreed between the Company and the Investor. The transfer of the Investment amount and issuance of the Shares pursuant
to Section 1.2 of this Agreement shall be subject to the completion of all of the following conditions and delivery of all of the
following approvals and instruments, all to the full satisfaction of the Investors and his legal counsel:

		4.1.1	Approval of this Agreement by the Company's Board of Directors ("Board
Approval").

		4.1.2	The approval of the TASE and the Nasdaq Capital Market for the listing
of the Shares.

		4.1.3	The receipt by the Investor of an electronic share certificates issued
to a registration company or one or more certificates dated the Closing Date and bearing appropriate legends. 

		4.1.4	The receipt by the Investor of a duly signed Company Shareholder
Register which includes the Shares.

A failure
to obtain the aforementioned approvals shall not subject the Company to any liability, provided that such failure is not a result
of the failure of the Company to perform any of its obligations under this Agreement.

		4.2	To the extent that the Board Approval shall have not been obtained by the end of day (Israel Time)
of Monday, January 2, 2017, the Investor may, at any time in its sole and absolute discretion, terminate this Agreement by a notice
to the Company without any liability or penalty.

		5.	BLOCKED SECURITIES

		5.1	Without derogating from Sections 1.8 and 3.4 above, according to the Israeli Securities Law, 1968-5,728
and the Securities Regulations (Information Regarding Sections 15A to 15C of the Law), 2000-5760, the following restrictions shall
apply to the sale of the Shares:

    
	Biondvax Investment Agreement	 	Page 7  of Page 13

     

    
		5.1.1	The Investor shall be prohibited from offering the Shares for sale
on TASE over a period of six months from the date the Shares were issued (the "Six Month Period").

		5.1.2	At the end of the Six Month Period and during the next 6 consecutive
quarters, the Investor may not offer to sell on TASE a quantity of the Shares which is higher than the average daily trade volume
of the same type of securities on TASE during an 8 week period prior to the date of such sale offer, and so long as the total amount
of the Shares sold by the shareholder on TASE is not greater than the aggregate amount of 1% of the issued and outstanding share
capital of the Company during a period of one Quarter. 

For the
purposes of this Agreement, a “Quarter" - a period of 3 months commencing at the end of the Six Month Period.

		6.	TAXES AND EXPENSES

Each
Party will bear its own taxes and expenses resulting from this Agreement. 

		7.	Miscellaneous

		7.1	This Agreement constitutes the full and entire understanding and agreement among the Parties with
regard to the subject matter hereof and supersedes and cancels any prior or contemporaneous agreements, understandings or discussions.

		7.2	Any term of this Agreement may be amended or waived with the prior written consent of the Company
and the Investor.

		7.3	This Agreement shall be governed by the laws of the State of Israel, without regard to the principles
of conflict of law thereof. Exclusive jurisdiction is hereby granted to the courts of Tel Aviv-Jaffa, Israel.

		7.4	Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit
of, and are binding upon, the successors, assigns, heirs, executors, and administrators of the Parties.

		7.5	None of the rights, privileges, or obligations of the Investor set forth in this Agreement may
be assigned or transferred by the Investor without the prior consent in writing of the Company.

		7.6	This Agreement may be executed in any number of counterparts, each of which shall be deemed an
original, and all of which together shall constitute one instrument.

		7.7	The terms and conditions of this Agreement and all non-public information received by the Investor
from the Company shall be maintain by the Parties in strict confidence, subject to the Company’s confidentiality obligations
pursuant to the Israeli Securities Law, the US Securities Law and Securities Regulations.

    
	Biondvax Investment Agreement	 	Page 8  of Page 13

     

    
		7.8	All notices and other communications required or permitted hereunder to be given to a Party to
this Agreement shall be in writing and shall be delivered by email, fax or hand delivery or by guaranteed courier, addressed to
such Party’s address as set forth below or at such other address as such Party shall have furnished to each other Party in
writing in accordance with this provision:

	
        If to Investor:

         

         

        With a copy to:

         
	
        Angels Investments in Hi Tech
        Ltd.,.

        18 Yehezkel St. Tel Aviv

        ___________________

        Email: yair.schindel@gmail.com

         

        Naschitz, Brandes Amir & Co.

        5 Tuval St.

        Tel Aviv

        03-623-5000

        Attn: Asher Assis

        Email: aassis@nblaw.com

	If to the Company:	
        BIONDVAX PHARMACEUTICALS LTD.

        14 Einstein Street, Nes-Ziona 74140,
        Israel

        Email: babecoff@biondvax.com

         

	With a copy to:	
        Pearl Cohen Zedek Latzer Baratz

        1 Azrieli Center, Round Tower, 18th
        floor

        Tel Aviv, Israel

        Attn: Ilan Gerzi, Adv.

 

[Signature
page follows]

    
	Biondvax Investment Agreement	 	Page 9  of Page 13

     

    

[Signature page to investment aGREEMENT]

IN WITNESS WHEREOF, the
Parties have executed this Agreement as of the date first hereinabove set forth. 

	
        COMPANY:

        BIONDVAX PHARMACEUTICALS LTD..

        By: _____________________

Name:
Ron Babecoff 

Title: Chief Executive Officer

         

         

         

         
	 	
        INVESTOR:

        ANGELS INVESTMENT IN HI TECH
        LTD

        By: _____________________

Name:
____________________

Title: Director

         

         

 

    
	Biondvax Investment Agreement	 	Page 10  of Page 13

     

    

EXHIBIT A 

 

[CAPTABLE]

 

 

    
	Biondvax Investment Agreement	 	Page 11  of Page 13

     

    

EXHIBIT B

 

		1.	Investor acknowledges and agrees that:

		(a)	the Shares have not been registered under the U.S. Securities Act of 1933, as amended (the "1933
Act"), or under any securities or "blue sky" laws of any state of the United States and are being offered only
in a transaction not involving any public offering within the meaning of the 1933 Act, and, unless so registered, may not be offered
or sold in the United States or to a U.S. Person, as that term is defined in Regulation “S” (“Regulation “S”)
promulgated by the Securities and Exchange Commission (the “SEC”) pursuant to the 1933 Act, except in accordance
with the provisions of Regulation "S", pursuant to an effective registration statement under the 1933 Act, or pursuant
to an exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act, and in each case only
in accordance with applicable state securities laws;

		(b)	the Company will refuse to register any transfer of any of the Shares not made in accordance with
the provisions of Regulation S, pursuant to an effective registration statement under the 1933 Act or pursuant to an available
exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act;

		(c)	Investor has not acquired the Shares as a result of, and will not itself engage in, any "directed
selling efforts" (as defined in Regulation S) in the United States in respect of any of the Securities which would include
any activities undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market
in the United States for the resale of any of the Shares; provided, however, that the Investor may sell or otherwise dispose of
any of the Shares pursuant to registration of any of the Shares pursuant to the 1933 Act and any applicable state securities laws
or under an exemption from such registration requirements and as otherwise provided herein;

    
	Biondvax Investment Agreement	 	Page 12  of Page 13

     

    
		(d)	Investor is not a U.S. Person (as defined in Regulation S), is outside the United States when receiving
and executing this Agreement and is acquiring the Shares as principal for its own account or as agent or trustee for a principal
that is not a U.S. Person (the "Disclosed Principal"), for investment purposes only, and not with a view to, or for,
resale, distribution or fractionalization thereof, in whole or in part, and no other person other than the Disclosed Principal
has a direct or indirect beneficial interest in such Shares;

		(e)	the statutory and regulatory basis for the exemption claimed for the offer and sale of the Units,
although in technical compliance with Regulation S, would not be available if the offering is part of a plan or scheme to evade
the registration provisions of the 1933 Act;

		(f)	the Company has advised the Investor that the Company is relying on an exemption from the requirements
to provide the Investor with a prospectus and to sell the Shares through a person registered to sell securities and, as a consequence
of acquiring the Shares pursuant to this exemption, certain protections, rights and remedies, including statutory rights of rescission
or damages, will not be available to the Investor;

		2.	Investor hereby represents and warrants to and covenants with the Company, as of the date of this Agreement and as of the
Closing Date (which representations, warranties and covenants shall survive the Closing Date) that:

		(a)	the Investor is outside the United States when receiving and executing this Agreement;

		(b)	the Investor is not a “U.S. Person”, as defined in Regulation S;

		(c)	the Investor is not acquiring the Shares for the account or benefit of, directly or indirectly,
any U.S. Person, as defined in Regulation S;

		(d)	the Investor is resident of the State of Israel;

In this Agreement,
the term "U.S. Person" shall have the meaning ascribed thereto in Regulation S promulgated under the 1933 Act and
for the purpose of the Subscription Agreement includes any person in the United States.

		(e)	The Investor hereby acknowledges that that upon the issuance thereof, and until such time as the
same is no longer required under the applicable securities laws and regulations, the certificates representing any of the Securities
will bear a legend in substantially the following form:

“THESE SECURITIES WERE ISSUED
IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE 1933 ACT) PURSUANT TO REGULATION S
UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”). ACCORDINGLY, NONE OF THE SECURITIES TO
WHICH THIS CERTIFICATE RELATES HAVE BEEN REGISTERED UNDER THE 1933 ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED,
NONE MAY BE OFFERED OR SOLD IN THE UNITED STATES OR, DIRECTLY OR INDIRECTLY, TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS
OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR PURSUANT TO AN EXEMPTION FROM, OR IN A
TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE 1933 ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN ACCORDANCE WITH
THE 1933 ACT.”

 

 

	Biondvax Investment Agreement	 	Page 13  of Page 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]